Diabetic retinopathy (DR) is an eye-related complication that can occur in people who have diabetes. It affects blood vessels in the retina - the "light-sensitive layer of tissue in the back of ...

Diabetic patients with high myopia have a significantly lower choroidal vascularity index (CVI) than those with diabetic retinopathy (DR), according to research published in Frontiers in Cell and ...

If it’s left untreated, diabetic retinopathy can lead to serious, sight-stealing complications. Here’s what to know.

Diabetic retinopathy occurs when high levels of blood sugar (a common marker of diabetes) damage the tiny blood vessels in the retina, a layer of tissue in the back of the eye that helps detect ...

A study reveals significant retinal vessel changes in diabetic retinopathy, highlighting the need for early detection methods ...

A sensitivity analysis of those who had type 2 diabetes for at least 5 years showed that cataract surgery was tied to increased 1-year risks of PDR without complications (HR 1.52, 95% CI 1.06-2.19 ...

R2 – preproliferative retinopathy: R2 – moderate BDR: High risk: 47 – moderate severe NPDR: ... Diabetic retinopathy (DR) is an important contributor to the burden of vision impairment.

Only 5 of the 11 diabetic patients were noted to have clinical diabetic retinopathy (although Case 5's ocular fundí are described as normal, they were not seen well because of bilateral ...

About Diabetic Retinopathy (DR) Diabetic retinopathy (DR) affects almost 10 million people in the U.S. and more than 100 million people globally, accounting for almost 5% of all cases of blindness.

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

SOUTH SAN FRANCISCO, Calif., May 22, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...